GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

Home
/
update
/
details

Paige Revolutionizes Cancer Research, Diagnostics, and Drug Development with Open-Sourcing of Virchow and PRISM, the First Million-Slide Foundation Model Suite

NextEdge Admin

03 Aug 2024

2 min 49 sec

Paige, a leader in AI-driven pathology solutions for cancer, announced the open-source release of its Foundation Models, Open Paige Foundation Model (OpenPFM), featuring Virchow and PRISM. These pioneering models, now available on Hugging Face, are designed to advance cancer research and clinical development. Virchow is the first million-slide foundation model for cancer, while PRISM, building on Virchow, is a vision and language model for comprehensive slide-level cancer insights. An ML SDK is also provided to support their use in the research community.

Developed with Microsoft Research, Virchow and PRISM aim to unlock deeper insights within pathology slides. Virchow's training data includes 1.5 million digitized slides from Memorial Sloan Kettering Cancer Center, one of the top cancer hospitals in the U.S. Published in Nature Medicine, Virchow sets a new standard in computational pathology, aiming to revolutionize cancer diagnosis and treatment.

PRISM enhances Virchow’s image representations, creating whole slide image signatures and generating written diagnostic summaries. Trained with an additional 587,000 slide images and 195,000 clinical reports, PRISM excels in tasks like cancer detection and subtyping without extra training. It improves data efficiency, reducing the number of training samples needed, and shows promise in biomarker prediction across various tissues.

Siqi Liu, Director of AI Science at Paige, emphasized the company’s commitment to fostering innovation and accessibility in AI research. Razik Yousfi, SVP of Technology at Paige, highlighted the goal of driving innovation and enhancing cancer diagnostics and drug development to transform patient care. Virchow is available under the Apache 2.0 License, while PRISM and the ML SDK are under the CC-BY-NC-ND 4.0 License. Advanced versions and commercial licensing options are available for clinical trials and R&D. Paige also offers collaboration opportunities to further scientific discoveries.